Abstract
Many cancer-testis antigen genes have been identified; however, few human leukocyte antigen (HLA)-A24-restricted cytotoxic T cell (CTL) epitope peptides are available for clinical immunotherapy. To solve this problem, novel tools increasing the efficacy and accuracy of CTL epitope detection are needed. In the present study, we utilized a highly active dendritic cell (DC)-culture method and an in silico HLA-A24 peptide-docking simulation assay to identify novel CTL epitopes from MAGE-A6 and MAGE-A12 antigens. The highly active DCs, called α-type-1 DCs, were prepared using a combination of maturation reagents to produce a large amount of interleukin-12. Meanwhile, our HLA-A24 peptide-docking simulation assay was previously demonstrated to have an obvious advantage of accuracy over the conventional prediction tool, bioinformatics and molecular analysis section. For CTL induction assays, peripheral blood mononuclear cells derived from six cases of HLA-A24+ melanoma were used. Through CTL induction against melanoma cell lines and peptide-docking simulation assays, two peptides (IFGDPKKLL from MAGE-A6 and IFSKASEYL from MAGE-A12) were identified as novel CTL epitope candidates. Finally, we verified that the combination of the highly active DC-culture method and HLA-A24 peptide-docking simulation assay might be tools for predicting CTL epitopes against cancer antigens.
Similar content being viewed by others
Abbreviations
- HLA:
-
Human leukocyte antigen
- DC:
-
Dendritic cell
- CTL:
-
Cytotoxic T cell
- BIMAS:
-
Bioinformatics and molecular analysis section
- PBMC:
-
Peripheral blood mononuclear cell
- CMV:
-
Cytomegalovirus
References
Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccine. Nat Med 10:909–915
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332
Matsuda K, Tsunoda T, Tanaka H, Umano Y, Tanimura H, Nukaya I, Takesako K, Yamaue H (2004) Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 53:609–616
Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL, Deleo AB (2000) A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinoma of the head and neck. Clin Cancer Res 6:979–986
Ueda Y, Shimizu K, Itoh T, Fuji N, Naito K, Shiozaki A, Yamamoto Y, Shimizu T, Iwamoto A, Tamai H, Yamagishi H (2007) Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides. Jpn J Clin Oncol 37:140–145
Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H (2005) Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 65:4936–4946
Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61(17):6451–6458
Akiyama Y, Tanosaki R, Inoue N, Shimada M, Hotate Y, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, Maruyama K, Takaue Y, Yamaguchi K (2005) Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med 3:4
Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E (2011) A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Feb3. doi:10.1002/ijc.25955
Tyagi P, Mirakhur B (2009) MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 10(5):371–374
Tsai JR, Chong IW, Chen YH, Yang MJ, Sheu CC, Chang HC, Hwang JJ, Hung JY, Lin SR (2007) Differential expression profile of MAGE family in non-small-cell lung cancer. Lung Cancer 56(2):185–192
Chung FY, Cheng TL, Chang HJ, Chiu HH, Huang MY, Chang MS, Chen CC, Yang MJ, Wang JY, Lin SR (2010) Differential gene expression profile of MAGE family in taiwanese patients with colorectal cancer. J Surg Oncol 102(2):148–153
Karn T, Pusztai L, Ruckhaberle E, Liedtke C, Muller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gatje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M (2011) Melanoma antigen family A identified by the biomodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer 48(1):12–23
Mailliard RB, Wankowicz-Kakinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P (2004) α-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64(17):5934–5937
Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC, Muthuswamy R, Kalinski P, Okada H (2009) Effective immunotherapy against murine gliomas using rtpe 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res 69(4):1587–1595
Nakamura Y, Tai S, Oshita C, Iizuka A, Ashizawa T, Saito S, Yamaguchi S, Kondo H, Yamaguchi K, Akiyama Y (2011) Analysis of HLA-A24-restricted peptides of carcinoembryonic antigen using a novel structure-based peptide-HLA docking algorithm. Cancer Sci 102(4):690–696. doi:10.1111/j.1349-7006.2011.01866.x
Akiyama Y, Maruyama K, Nara N, Mochizuki T, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, Yamaguchi K (2004) Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. Anticancer Res 24:571–577
Knorr R, Trzeciak A, Bannwarth W, Gillessen D (1989) New coupling reagents in peptide chemistry. Tetrahedron Lett 30:1927–1930
Fujie T, Tahara K, Tanaka F, Mori M, Takesako K, Akiyoshi T (1999) A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer 80(2):169–172
Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T (1999) Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 5(8):2236–2241
Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, Celis E, Akiyoshi T (1997) Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocyte antigen-A24. Cancer Res 57:4465–4468
Jia ZC, Ni B, Huang ZM, Tian Y, Tang J, Wang JX, Fu XL, Wu YZ (2010) Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4. Clin Dev Immunol Epub 2011 Feb14
Jia ZC, Tian Y, Huang ZM, Wang JX, Fu XL, Ni B, Wu YZ (2011) Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells. Cancer Biol Ther 11(4):395–400
Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K (2002) Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 169(1):575–580
Acknowledgments
We thank Dr. Mochizuki for supplying several synthetic peptides and technical assistance. This work was supported by a grant from the Cooperation of Innovative Technology and Advanced Research in Evolutional Area (CITY AREA) program from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
262_2012_1298_MOESM1_ESM.ppt
Expanded view of the subset of genes whose expression was specifically increased in melanoma cell lines, not in melanocytes, from a high density oligonucleotide assay. Each row corresponds to a single gene, and the columns correspond to gene expression levels in different samples. The color saturation reflects the fold increase of expression intensity compared to that of melanocytes ranging from blue to red. The top 30 genes specifically expressed in melanoma (positive in more than 6 of 10 melanoma cell lines), not in melanocytes, are shown. The MAGE-A1, -A2, -A3 and -A12 genes were all included in the top 30. Supplementary material 1 (PPT 373 kb)
Rights and permissions
About this article
Cite this article
Akiyama, Y., Komiyama, M., Nakamura, Y. et al. Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay. Cancer Immunol Immunother 61, 2311–2319 (2012). https://doi.org/10.1007/s00262-012-1298-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-012-1298-1